Clinical Trial

A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis

Study acronym: VELOTA
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate how well the study drug JNJ-88545223 works compared with a placebo (an inactive substance) in adults with active psoriatic arthritis (PsA). The study aims to see whether treatment with JNJ-88545223 can help reduce the signs and symptoms of PsA and improve joint and skin health.
Protocol Amendment History 4 changes
notable Trial sites expanded: 68 -> 72 locations 2026-07-07
notable Trial sites expanded: 63 -> 68 locations 2026-06-06
notable Trial sites expanded: 40 -> 63 locations 2026-06-03
notable Trial sites expanded: 19 -> 40 locations 2026-04-14
Trial Details
NCT Number NCT07321873
Lead Sponsor Janssen Research & Development, LLC
Conditions Arthritis, Psoriatic
Enrollment 240 participants
Start Date 2026-01-15
Primary Completion 2027-06-28 (estimated)
Study Completion 2027-08-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-31